ConductScience.org, home
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
API referenceFor AI assistants

Trial · NCT04256421

Results by group73

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 73

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Investigator-Assessed Progression Free Survival (PFS) in the Primary Analysis Set (PAS)Placebo + Atezolizumab5.5595% Confidence Interval 5.36 to 5.85months
Investigator-Assessed Progression Free Survival (PFS) in the Primary Analysis Set (PAS)Tiragolumab + Atezolizumab5.3695% Confidence Interval 4.67 to 5.52months
Overall Survival (OS) in the PASPlacebo + Atezolizumab13.1495% Confidence Interval 12.16 to 15.11months
Overall Survival (OS) in the PASTiragolumab + Atezolizumab13.1195% Confidence Interval 10.84 to 14.39months
PFS in the FASPlacebo + Atezolizumab5.4295% Confidence Interval 4.47 to 5.65months
PFS in the FASTiragolumab + Atezolizumab5.0695% Confidence Interval 4.40 to 5.42months
OS in the FASPlacebo + Atezolizumab12.9195% Confidence Interval 11.99 to 14.52months
OS in the FASTiragolumab + Atezolizumab12.7595% Confidence Interval 10.84 to 14.29months
Investigator-Assessed Confirmed Objective Response Rate (ORR) in the PASPlacebo + Atezolizumab66.795% Confidence Interval 59.64 to 73.05percentage of participants
Investigator-Assessed Confirmed Objective Response Rate (ORR) in the PASTiragolumab + Atezolizumab73.595% Confidence Interval 66.61 to 79.39percentage of participants
Investigator-Assessed Confirmed ORR in the FASPlacebo + Atezolizumab65.695% Confidence Interval 59.26 to 71.42percentage of participants
Investigator-Assessed Confirmed ORR in the FASTiragolumab + Atezolizumab70.895% Confidence Interval 64.56 to 76.33percentage of participants
Investigator-Assessed Duration of Response (DOR) in the PASPlacebo + Atezolizumab5.5995% Confidence Interval 4.57 to 6.93months
Investigator-Assessed Duration of Response (DOR) in the PASTiragolumab + Atezolizumab4.1995% Confidence Interval 4.14 to 4.60months
Investigator-Assessed DOR in the FASPlacebo + Atezolizumab5.1195% Confidence Interval 4.37 to 5.75months
Investigator-Assessed DOR in the FASTiragolumab + Atezolizumab4.1795% Confidence Interval 4.07 to 4.37months
Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PASPlacebo + AtezolizumabMonth 642.4295% Confidence Interval 35.54 to 49.31percentage of participants
Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PASTiragolumab + AtezolizumabMonth 635.1595% Confidence Interval 28.41 to 41.90percentage of participants
Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PASPlacebo + AtezolizumabMonth 1217.2995% Confidence Interval 11.90 to 22.69percentage of participants
Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PASTiragolumab + AtezolizumabMonth 1214.2195% Confidence Interval 9.06 to 19.35percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04256421/results

API referenceFor AI assistants